This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982; 300: 765–767.
De Klein A, Hagemeijer A, Bartram CR, Houwen R, Hoefsloot L, Carbonell F et al. bcr rearrangement and translocation of the c-abl oncogene in Philadelphia positive acute lymphoblastic leukemia. Blood 1986; 68: 1369–1375.
Van Limbergen H, Beverloo HB, van Drunen E, Janssens A, Hahlen K, Poppe B et al. Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. Genes Chromosomes Cancer 2001; 30: 274–282.
Graux C, Cools J, Melotte C, Quentmeier H, Ferrando A, Levine R et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004; 36: 1084–1089.
De Keersmaecker K, Graux C, Odero MD, Mentens N, Somers R, Maertens J et al. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood 2005; 105: 4849–4852.
De Braekeleer E, Douet-Guilbert N, Le Bris MJ, Berthou C, Morel F, De Braekeleer M . A new partner gene fused to ABL1 in a t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia. Leukemia 2007; 21: 2220–2221.
Sharma M, Li X, Wang Y, Zarnegar M, Huang CY, Palvimo JJ et al. hZimp10 is an androgen receptor co-activator and forms a complex with SUMO-1 at replication foci. EMBO J 2003; 22: 6101–6114.
Li X, Thyssen G, Beliakoff J, Sun Z . The novel PIAS-like protein hZimp10 enhances Smad transcriptional activity. J Biol Chem 2006; 281: 23748–23756.
Lee J, Beliakoff J, Sun Z . The novel PIAS-like protein hZimp10 is a transcriptional co-activator of the p53 tumor suppressor. Nucleic Acids Res 2007; 35: 4523–4534.
Acknowledgements
We thank S Nusbaum, F Poulain and MC Waill for valuable help. This work was supported by INSERM, L'Association pour la Recherche sur le Cancer (ARC) and INCa Grants PL038 and PL054.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Soler, G., Radford-Weiss, I., Ben-abdelali, R. et al. Fusion of ZMIZ1 to ABL1 in a B-cell acute lymphoblastic leukaemia with a t(9;10)(q34;q22.3) translocation. Leukemia 22, 1278–1280 (2008). https://doi.org/10.1038/sj.leu.2405033
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2405033
This article is cited by
-
Dasatinib for chronic myelomonocytic leukemia with ZMIZ1-ABL1 fusion gene: a case report
International Journal of Hematology (2023)
-
ZMIZ proteins: partners in transcriptional regulation and risk factors for human disease
Journal of Molecular Medicine (2022)
-
A novel ABL1 fusion to the SH2 containing inositol phosphatase-1 (SHIP1) in acute lymphoblastic leukemia (ALL)
Leukemia (2011)
-
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders
Leukemia (2008)